2. Search Result
Search Result
Results for "

inactive control

" in MedChemExpress (MCE) Product Catalog:

59

Inhibitors & Agonists

2

Biochemical Assay Reagents

16

Peptides

2

Natural
Products

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-121954
    Necrostatin-1 (inactive control)

    Nec-1 (inactive control)

    		 Necroptosis Cancer
    Necrostatin-1 (Nec-1) (inactive control) is an inactive analog of Necrostatin-1 (HY-15760). Necrostatin-1 is a potent necroptosis inhibitor .
    Necrostatin-1 (inactive control)
  • HY-136453A
    CR-1-30-B

    		Mucin Drug Isomer Cancer
    CR-1-30-B is an inactive enantiomer of CR-1-31-B. CR-1-30-B, as a control, is inactive against eIF4A and has no apparent effect on the induction of MUC1-C translation .
    CR-1-30-B
  • HY-118914
    Glucagon receptor antagonist inactive control

    		GCGR
    Glucagon receptor antagonist inactive control (Compound 2) is a compound structurally similar to the glucagon receptor (GCGR) antagonist Glucagon receptor antagonist (Compound 1) but lacks antagonistic activity against glucagon receptor (GCGR). Glucagon receptor antagonist inactive control can be used as a negative control to study mechanisms related to glucagon receptor-mediated signaling pathways .
    Glucagon receptor antagonist inactive control
  • HY-113894
    Retreversine

    		Aurora Kinase Cancer
    Retreversine is an inactive control for Reversine. Reversine is a novel class of ATP-competitive Aurora kinase inhibitor .
    Retreversine
  • HY-129253
    GSK984

    		HPV Infection
    GSK984 is an inactive control probe for GSK983 (HY-119098), a dihydroorotate dehydrogenase (DHODH) inhibitor with antiviral activity .
    GSK984
  • HY-P2670
    SN50M

    		NF-κB Others
    SN50M, a mutant peptide of SN50 (HY-P0151), is a cell membrane-permeable inactive control peptide .
    SN50M
  • HY-P3970C
    KQFK

    		TGF-β Receptor Others
    KQFK is an inactive control of KRFK (HY-P3970). KRFK is a peptide derived from TSP-1 that can activate TGF-β .
    KQFK
  • HY-161408A
    iGePhos1

    		Phosphatase Others
    iGePhos1 is an inactive GePhos1 (HY-161408) epimer used as a nonbinding negative control. iGephos1 lacks the phosphatase recruiting possibility .
    iGePhos1
  • HY-P1402
    [Glu27]-PKC (19-36)

    		PKC Others
    [Glu27]-PKC (19-36) is an inactive control for protein kinase C (PKC) (19-36). PKC (19-36) is a pseudosubstrate peptide inhibitor of protein kinase C, it may be responsible for maintaining the enzyme in the inactive form in the absence of allosteric activators such as phospholipids .
    [Glu27]-PKC (19-36)
  • HY-145081
    Pitnot-2

    		Others Infection
    Pitnot-2 is an inactive analog of clathrin inhibitor Pitstop 2. Pitnot-2 can be used as negative control .
    Pitnot-2
  • HY-15517B
    KN-92 hydrochloride
    Maximum Cited Publications
    6 Publications Verification

    		 CaMK Cancer
    KN-92 hydrochloride is an inactive derivative of KN-93, without CaM kinase inhibitory activity. KN-92 hydrochloride is intended to be used as a control compound in studies designed to elucidate the antagonist activities of KN-93 .
    KN-92 hydrochloride
  • HY-118421
    Nullscript

    		Parasite HDAC Infection
    Nullscript is a negative control for Scriptaid. Nullscript is a known inactive analog of Scriptaid . Scriptaid is a representative HDAC inhibitor . Nullscript inhibits Cryptosporidium (C. parvum) growth with the IC50 value of 2.1 μM .
    Nullscript
  • HY-15517A
    KN-92 phosphate
    Maximum Cited Publications
    6 Publications Verification

    		 CaMK Autophagy Cancer
    KN-92 phosphate is an inactive derivative of KN-93, without CaM kinase inhibitory activity. KN-92 phosphate is intended to be used as a control compound in studies designed to elucidate the antagonist activities of KN-93. KN-93 is a cell-permeable, reversible and competitive CaMKII inhibitor .
    KN-92 phosphate
  • HY-15517
    KN-92
    Maximum Cited Publications
    6 Publications Verification

    		 CaMK Cancer
    KN-92 is an inactive derivative of KN-93, without CaM kinase inhibitory activity. KN-92 is intended to be used as a control compound in studies designed to elucidate the antagonist activities of KN-93. KN-93 is a cell-permeable, reversible and competitive CaMKII inhibitor .
    KN-92
  • HY-101125B
    D-Moses

    D-45

    		 Epigenetic Reader Domain Cancer
    D-Moses (D-45) is an enantiomer of L-Moses (HY-101125). L-Moses (L-45) is a potent and selective p300/CBP-associated factor (PCAF) bromodomain (Brd) inhibitor. D-Moses shows no observable binding for PCAF Brd. D-Moses can be used as an inactive control compound to L-Moses .
    D-Moses
  • HY-16994
    OICR-0547

    		WDR5 Cancer
    OICR-0547 is a negative control, closely related derivative of OICR-9429 (HY-16993). OICR-9429 is a novel small-molecule antagonist of the Wdr5-MLL interaction. OICR-0547 is an inactive control compound that no longer binds to WDR5 .
    OICR-0547
  • HY-119857
    AGK7

    SIRT2 Inhibitor,inactive control

    		 Sirtuin Neurological Disease
    AGK7 is a potent inhibitor of sirtuin 2 (SIRT2). AGK7 rescues alpha-synuclein toxicity and modified inclusion morphology in a cellular model of Parkinson's disease. AGK7 protects against dopaminergic cell death both in vitro and in a Drosophila model of Parkinson's disease .
    AGK7
  • HY-P1849A
    JAG-1, scrambled TFA

    scJag-1 TFA

    		 Notch Cardiovascular Disease
    JAG-1, scrambled (scJag-1) TFA is a scrambled sequence of JAG-1 (Jagged-1 protein). JAG-1, scrambled TFA has a random sequence of the amino acids that are the same as the active fragment. JAG-1, scrambled TFA is usually used as a negative control .
    JAG-1, scrambled TFA
  • HY-126300A
    SGC6870N

    		Histone Methyltransferase Cancer
    SGC6870N is inactive against PRMT6 and can be utilized as a negative control. SGC6870N is an inactive enantiomer of SGC6870 (HY-126300) .
    SGC6870N
  • HY-148745
    JG-258

    		HSP Cancer
    JG-258 is an inactive negative control for Hsp70 inhibitors .
    JG-258
  • HY-153918A
    (S)-SKBG-1

    		Ligands for Target Protein for PROTAC Cancer
    (S)-SKBG-1 is an inactive and covalent NONO ligand, used for assay control..
    (S)-SKBG-1
  • HY-P1312
    LRGILS-NH2

    		Protease Activated Receptor (PAR) Others
    LRGILS-NH2 is a reverse-sequence protease-activated receptor-2 (PAR-2)-inactive, negative control, and SLIGRL-NH2 is a PAR-2-activating peptide .
    LRGILS-NH2
  • HY-P1312A
    LRGILS-NH2 TFA

    		Protease Activated Receptor (PAR) Others
    LRGILS-NH2 TFA is a reverse-sequence protease-activated receptor-2 (PAR-2)-inactive, negative control, and SLIGRL-NH2 is a PAR-2-activating peptide .
    LRGILS-NH2 TFA
  • HY-120343
    GSK106

    		Protein Arginine Deiminase Cardiovascular Disease Inflammation/Immunology Cancer
    GSK106 is an inactive control for the selective PAD4 inhibitors, GSK484 and GSK199 .
    GSK106
  • HY-106029
    4α-TPA

    α-TPA

    		 PKC SphK NF-κB Cancer
    4α-TPA is an inactive form of TPA, and is used as a negative control for TPA-activated events .
    4α-TPA
  • HY-121733
    PHGDH-inactive

    		Phosphoglycerate Dehydrogenase (PHGDH) Cancer
    PHGDH-inactive has no activity against PHGDH and serves as a negative control of NCT-502 and NCT-503 .
    PHGDH-inactive
  • HY-124479A
    γ-Lumicolchicine

    		Drug Derivative Cancer
    γ-Lumicolchicine is an inactive analogue of Colchicine (HY-16569) that can be used as an experimental control for Colchicine action .
    γ-Lumicolchicine
  • HY-154843
    C-Gem

    		TrxR Cancer
    C-Gem is a control molecule of S-Gem (HY-154842). C-Gem is completely inactive under experimental conditions .
    C-Gem
  • HY-P10168
    11R-CaN-CON

    		Phosphatase Others
    11R-CaN-CON is a control inactive peptide and can be used as a negative control for 11R-CaN-AID (HY-P10167) .
    11R-CaN-CON
  • HY-107477
    GSK8573

    		Epigenetic Reader Domain Cancer
    GSK8573 is an inactive control compound for GSK2801 (acetyl-lysine competitive inhibitor of BAZ2A and BAZ2B bromodomains). GSK8573 has binding activity to BRD9 with a Kd value of 1.04 μM and is inactive against BAZ2A/B and other bromodomain familiy. GSK8573 can be used as a structurally related negative control compound in biological experiments .
    GSK8573
  • HY-155221
    UNC7145

    		Histone Methyltransferase Cancer
    UNC7145 is an inactive derivative of UNC6934 (HY-145103) that can be used as a negative control for the protein-protein inhibition activity of UNC6934.
    UNC7145
  • HY-153887
    HyT36(-Cl)

    		EGFR Others
    HyT36(-Cl) is the inactive control compound of HyT36, a small molecule hydrophobic tag compound that can be used in protein folding research .
    HyT36(-Cl)
  • HY-P2250
    ELA RR>GG

    ELA-32 negative control

    		 Apelin Receptor (APJ) Others
    ELA RR>GG (ELA-32 negative control), an ELABELA (ELA-32 human) mutant peptide, is inactive. ELA RR>GG is a negative control for ELABELA (HY-P2196) .
    ELA RR>GG
  • HY-135843
    TH-263

    		LIM Kinase (LIMK) Cancer
    TH-263, a diaryl sulfonamide derivative, is inactive toward both LIMK1 and LIMK2 and thus can be used as negative control for TH-257 .
    TH-263
  • HY-13851
    PS47

    		PDK-1 Others
    PS47 is an inactive E-isomer of PS48. PS48 is an activator of PDK1. PS47 can be used as a negative control for PS48 .
    PS47
  • HY-112464
    PKR Inhibitor, negative control

    		Pyruvate Kinase Neurological Disease
    PKR Inhibitor, negative control is an inactive structural analog of RNA-dependent protein kinase (PKR) inhibitor, which can be used as a negative control. PKR Inhibitor, negative control can also inhibit LK-induced neuronal death, exhibiting significant neuroprotective effects .
    PKR Inhibitor, negative control
  • HY-P2243
    D-JBD19

    		JNK Neurological Disease
    D-JBD19 is an impermeable peptide that serves as an inactive control for the JNK inhibitor D-JNKI1 (HY-P0069). D-JNKI1 has neuroprotective effects .
    D-JBD19
  • HY-145056
    ART615

    		DNA/RNA Synthesis Cancer
    ART615 is the related isomer of ART558. ART615, the inactive of ART558, elicits <10% Polθ inhibition at 12 µM, thus serving as a control for ART558 (IC50=7.9 nM) .
    ART615
  • HY-125143
    ABC34

    		MAGL Metabolic Disease
    ABC34 is an inactive control compound of JJH260. ABC34 does not inhibit the fluorophosphonate reactivity or fatty acid esters of hydroxy fatty acid (FAHFA) hydrolysis activity of AIG1. ABC34 can inhibit both ABHD6 and PPT122 .
    ABC34
  • HY-P3970D
    KQFK TFA

    		TGF-β Receptor Inflammation/Immunology
    KQFK TFA is the TFA salt form of KQFK (HY-P3970C). KQFK TFA is an inactive control of KRFK (HY-P3970). KRFK is a peptide derived from TSP-1 that can activate TGF-β .
    KQFK TFA
  • HY-108437
    exo-IWR-1

    		Wnt Infection Cancer
    exo-IWR-1, an inactive stereoisomer of Endo-IWR-1, is a negative control of IWR-1 (HY-12238). IWR-1 is a tankyrase inhibitor which inhibits Wnt/β-catenin signaling pathway .
    exo-IWR-1
  • HY-115682
    (S)-ZINC-3573

    		Mas-related G-protein-coupled Receptor (MRGPR) Others
    (S)-ZINC-3573 is an inactive enantiomer of ZINC-3573. (R)-ZINC-3573 is a selective MRGPRX2 agonist. (S)-ZINC-3573 and (R)-ZINC3573 are effective and internally controlled probe-pairs for investigating the biology of primate-exclusive receptor .
    (S)-ZINC-3573
  • HY-P3882
    Fmoc-Ala-Glu-Gln-Lys-NH2

    		Amino Acid Derivatives Neurological Disease
    Fmoc-Ala-Glu-Gln-Lys-NH2 (AEQK) is a tetrapeptide. Fmoc-Ala-Glu-Gln-Lys-NH2 is the inactive control for Fmoc-Ala-Glu-Asn-Lys-NH2 (AENK) peptide inhibitor. AENK blocks proteolysis of UNC5C protein .
    Fmoc-Ala-Glu-Gln-Lys-NH2
  • HY-111457
    BAY-677

    		Elastase Inflammation/Immunology
    BAY-677 is an inactive control for BAY-678. BAY-678 is an orally bioavailable, highly potent, selective and cell-permeable inhibitor of human neutrophil elastase (HNE), with an IC50 of 20 nM . BAY-678 is also nominated as a chemical probe to the public via the Structural Genomics Consortium (SGC) .
    BAY-677
  • HY-116429A
    7(S)-Maresin 1

    		Reactive Oxygen Species Inflammation/Immunology
    7(S)-Maresin 1 is an inactive 7(S) exomer of Maresin 1, containing a 7(R) hydroxyl group. It can be used as a negative control. Maresin 1 is a specific regulator of endogenous DHA production in the human body, which can stimulate the production and secretion of intracellular Ca 2+ .
    7(S)-Maresin 1
  • HY-108630
    U-73343
    4 Publications Verification

    		 Phospholipase Others
    U-73343, works as a protonophore, is an inactive analog of U-73122 and can be used as a negative control. U-73343 dose-dependently inhibits acid secretion irrespective of the stimulant. U-73122 is a phospholipase C (PLC) and 5-LO (5-lipoxygenase) inhibitor with an IC50 of 1-2.1 µM for PLC .
    U-73343
  • HY-135416
    Streptolysin O

    		Endogenous Metabolite Infection
    Streptolysin O, a group A streptococcal toxin, is a well-characterized oxygen-labile prototype of a cholesterol-binding bacterial exotoxin. Streptolysin O causes both lysis of cells and cardiotoxicity. Streptolysin O is widely used for the controlled permeabilization of cell membranes. Streptolysin O exists in two forms, a reduced active state and an oxidized reversibly inactive state .
    Streptolysin O
  • HY-78931B
    (S,S,S,S,R)-Boc-Dap-NE

    		Drug Intermediate Cancer
    (S,S,S,S,R)-Boc-Dap-NE is the inactive isomer of Boc-Dap-NE (HY-78931), and can be used as an experimental control. Boc-Dap-NE, is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.
    (S,S,S,S,R)-Boc-Dap-NE
  • HY-78931A
    (R,S,S,R,S)-Boc-Dap-NE

    		Drug Intermediate Cancer
    (R,S,S,R,S)-Boc-Dap-NE is the inactive isomer of Boc-Dap-NE (HY-78931), and can be used as an experimental control. Boc-Dap-NE, is an intermediate in the synthesis of Monomethyl auristatin E (HY-15162), which is an inhibitor of tubulin polymerization. Monomethyl auristatin E can be used to synthesize Antibody-Drug Conjugates (ADCs) as ADC Cytotoxin.
    (R,S,S,R,S)-Boc-Dap-NE
  • HY-145082
    4-Sulfo-N-(4-aminobenzyl)-1,8-naphthalimide potassium

    		Drug Derivative Others
    4-Sulfo-N-(4-aminobenzyl)-1,8-naphthalimide potassium is an inactive 1,8-Naphthalimide derivative. 4-Sulfo-N-(4-aminobenzyl)-1,8-naphthalimide potassium can be used as a negative control for the clathrin inhibitor 3-Sulfo-N-benzyl-1,8-naphthalimide, potassium salt .
    4-Sulfo-N-(4-aminobenzyl)-1,8-naphthalimide potassium

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: